Compare IMCR & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMCR | WD |
|---|---|---|
| Founded | 2008 | 1937 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2021 | 2010 |
| Metric | IMCR | WD |
|---|---|---|
| Price | $33.44 | $63.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $64.30 | ★ $83.33 |
| AVG Volume (30 Days) | ★ 350.2K | 257.9K |
| Earning Date | 02-25-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 4.10% |
| EPS Growth | N/A | ★ 20.18 |
| EPS | N/A | ★ 3.37 |
| Revenue | $379,590,000.00 | ★ $1,160,070,000.00 |
| Revenue This Year | $32.42 | $21.20 |
| Revenue Next Year | $11.17 | $10.20 |
| P/E Ratio | ★ N/A | $19.41 |
| Revenue Growth | ★ 28.11 | 17.65 |
| 52 Week Low | $23.15 | $58.60 |
| 52 Week High | $40.72 | $97.70 |
| Indicator | IMCR | WD |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 51.39 |
| Support Level | $32.00 | $62.56 |
| Resistance Level | $33.92 | $66.47 |
| Average True Range (ATR) | 1.47 | 1.68 |
| MACD | 0.01 | 0.67 |
| Stochastic Oscillator | 41.57 | 63.91 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.